Oil-in-water-type compound nitazoxanid nanoemulsion and preparation method thereof

Abstract

The invention discloses an oil-in-water-type compound nitazoxanid nanoemulsion combination, wherein, the particle size of nanoemulsion ranges from 1 to 100 nm, and the oil-in-water-type compound nitazoxanid nanoemulsion combination comprises the following raw materials by mass percent: surface-active agents accounting for 19.0 to 35.0 percent, cosurfactants accounting for 0 to 7.0 percent, nitazoxanid accounting for 0.01 to 0.21 percent, cinnamic aldehyde accounting for 0.1 to 8.0 percent and distilled water that is the rest ingredient; and the sum of the mass percent of the raw materials is 100 percent. The nanoemulsion improves the solvability of nitazoxanid and the medical bioavailability, improves the curative effects of medicines, reduces the medicine dose, has higher activity of resisting protozoa, worms, bacteria, virus and the like, and is used for treating diseases of people or livestocks caused by protozoa, the worms, the bacteria, virus and the like. The oil-in-water-type compound nitazoxanid nanoemulsion combination is safe to use, has the advantages of obvious curative effects, simple preparation method and wide market prospect in medicine field, and is convenient to popularize and apply.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a drug that can be used for human or livestock protozoa (Cryptosporidium parvum, amoeba, etc.), worms (most nematodes, tapeworms and trematodes), bacteria (gram-positive bacteria and An oil-in-water type compound nitazoxanide nanoemulsion for the treatment of diseases caused by infections such as Gram-negative bacteria) and viruses (rotavirus, etc.) and a preparation method thereof. Background technique [0002] Nitazoxin is especially called nitazolamide; o-[N-(5-nitrothiazol-2-yl)carbamoyl]phenol acetate is a derivative of nitrothiasalicylic acid amide. It was first successfully developed by Romark Laboratories in the 1970s, and it was first launched in Mexico in 1996 as an antiparasitic drug. English trade names: Daxon and Colufase, later listed in Australia, New Zealand, the United States and other countries, trade name CryptazTM, listed dosage forms are tablets (500mg) and dry suspens...

AI Technical Summary

Problems solved by technology

Tablets are traditional preparations and commonly used preparations, which need to be prepared by adding excipients and compressing. After oral administration, the drug dissolves slowly, has low bioavailability, and has the disadvantage of being difficult to swallow for some special patients; suspension The drug particles in the drug are generally between 0.5 and 10 μm, which is a thermodynamically unstable coarse dispersion system with low bioavailability and poor stability.